New registry aims to sharpen use of precision radiation for cancer
NCT ID NCT02170181
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study created a registry of 149 cancer patients who received a precise type of radiation called SBRT. The goal was to track how doctors use this treatment in four different situations: for cancer that has spread to a few spots, after chemotherapy, before starting chemotherapy, or when cancer returns after previous radiation. By collecting this information, researchers hope to better understand the best ways to use SBRT and improve future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stereotactic body radiation therapy (SBRT)
- What this could lead to
- If successful, this registry could help doctors better understand when and how to use SBRT for cancer that has spread, potentially improving treatment decisions.
- What could go wrong
- This is an observational registry, not a treatment trial, so it won't directly test if SBRT works better than other options. Results may not apply to all cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER PATIENTS RECEIVING STEREOTACTIC BODY RTX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?